# National Vision (EYE) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/EYE
## Company Profile
- Ticker: EYE
- Exchange: NASDAQ
- Sector: Biotechnology
- Location: United States
- Tags: Biopharma, Diagnostics, Novel Therapies, Gene Therapy, Inherited Retinal Disease Gene Therapy, Ophthalmology
## Stock Data
- Close: 20.73 USD
- Market cap: 1566280800.75 USD
- Last updated: 2026-07-17
## Business Overview
National Vision is an ophthalmology-focused biopharmaceutical company centered on eye-disease programs where clinical validation and specialty adoption drive the narrative.
## Why The Stock Is Moving

EYE is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, National Vision is followed within the ophthalmology universe for its exposure to specialty-treatment catalysts and clinical milestones.

## Business Model

National Vision is a specialty-disease story where pipeline execution, physician adoption, and label progress shape how investors value the company.

## Landscape Position

Compared with larger diversified peers, National Vision sits closer to the catalyst-driven side of the landscape, where ophthalmology updates can shift expectations quickly.

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.